Literature DB >> 25061167

Writing guidelines without a net: ECD.

Oussama Abla1, Robert Arceci2.   

Abstract

Mesh：

Year:  2014        PMID： 25061167      PMCID： PMC4110651          DOI： 10.1182/blood-2014-06-578997

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

Review 1.  Langerhans cell histiocytosis and Erdheim-Chester disease.

Authors:  Marta Wilejto; Oussama Abla
Journal:  Curr Opin Rheumatol       Date:  2012-01       Impact factor: 5.006

2.  High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.

Authors:  Julien Haroche; Frédéric Charlotte; Laurent Arnaud; Andreas von Deimling; Zofia Hélias-Rodzewicz; Baptiste Hervier; Fleur Cohen-Aubart; David Launay; Annette Lesot; Karima Mokhtari; Danielle Canioni; Louise Galmiche; Christian Rose; Marc Schmalzing; Sandra Croockewit; Marianne Kambouchner; Marie-Christine Copin; Sylvie Fraitag; Felix Sahm; Nicole Brousse; Zahir Amoura; Jean Donadieu; Jean-François Emile
Journal:  Blood       Date:  2012-08-09       Impact factor: 22.113

3.  BRAF mutations in Erdheim-Chester disease.

Authors:  Jean-François Emile; Frédéric Charlotte; Zahir Amoura; Julien Haroche
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

4.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

5.  New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.

Authors:  Matteo S Carlino; Vu Kwan; David K Miller; Catherine A B Saunders; Desmond Yip; Adnan M Nagrial; Jeanne Tomlinson; Sean M Grimmond; Richard A Scolyer; Richard F Kefford; Andrew V Biankin; Georgina V Long
Journal:  J Clin Oncol       Date:  2014-05-12       Impact factor: 44.544

6.  CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.

Authors:  Laurent Arnaud; Baptiste Hervier; Antoine Néel; Mohamed A Hamidou; Jean-Emmanuel Kahn; Bertrand Wechsler; Gemma Pérez-Pastor; Bjørn Blomberg; Jean-Gabriel Fuzibet; François Dubourguet; António Marinho; Catherine Magnette; Violaine Noel; Michel Pavic; Jochen Casper; Anne-Bérangère Beucher; Nathalie Costedoat-Chalumeau; Laurent Aaron; Juan Salvatierra; Carlos Graux; Patrice Cacoub; Véronique Delcey; Claudia Dechant; Pascal Bindi; Christiane Herbaut; Giorgio Graziani; Zahir Amoura; Julien Haroche
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

Review 7.  Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases.

Authors:  C Veyssier-Belot; P Cacoub; D Caparros-Lefebvre; J Wechsler; B Brun; M Remy; B Wallaert; H Petit; A Grimaldi; B Wechsler; P Godeau
Journal:  Medicine (Baltimore)       Date:  1996-05       Impact factor: 1.889

8.  BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.

Authors:  Maria Giulia Cangi; Riccardo Biavasco; Giulio Cavalli; Greta Grassini; Elena Dal-Cin; Corrado Campochiaro; Barbara Guglielmi; Alvise Berti; Vito Lampasona; Andreas von Deimling; Maria Grazia Sabbadini; Marina Ferrarini; Claudio Doglioni; Lorenzo Dagna
Journal:  Ann Rheum Dis       Date:  2014-03-26       Impact factor: 19.103

9.  Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.

Authors:  Julien Haroche; Fleur Cohen-Aubart; Jean-François Emile; Laurent Arnaud; Philippe Maksud; Frédéric Charlotte; Philippe Cluzel; Aurélie Drier; Baptiste Hervier; Neïla Benameur; Sophie Besnard; Jean Donadieu; Zahir Amoura
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.